Navigation Links
Cell Genesys to Present at the BIO CEO and Investor Conference
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO and Investor Conference in New York, New York, on Monday, February 11, 2008 at 11:00 a.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Contact:

Susan Ferris

Investor Relations

650-266-3200


'/>"/>
SOURCE Cell Genesys
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... and biotech research and development (R&D), today announced the establishment of Genedata Limited ... Managing Director Kevin Teburi, a recognized expert in life science informatics. Creating the ...
(Date:2/21/2017)... ... 21, 2017 , ... Creation Technologies, a private company and ... manufacturers (OEMs) , today announced it has received the ‘Highest Overall Customer Rating’ ... its category of electronics manufacturing services (EMS) providers with annual revenues over $500 ...
(Date:2/21/2017)... 21, 2017   Invitae Corporation (NYSE: NVTA), ... announced that members of the company,s management team will ... Care Conference on Monday, March 6, 2017 at approximately ... Boston, Massachusetts . The ... by visiting the investors section of the company,s website ...
(Date:2/20/2017)... 20, 2017 This report analyzes the worldwide markets ... Types: Xylanase, Amylase, Cellulase, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Read the ... forecasts are provided for the period 2015 through 2022. Also, ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/30/2017)... SAN FRANCISCO , Jan. 30, 2017   ... of the fastest growing genetic information companies, today announced ... 2016 financial results and provide 2017 guidance on Monday, ... a conference call that day at 4:45 p.m. Eastern ... call, Invitae,s management team will briefly review financial results, ...
Breaking Biology News(10 mins):